Annandale, NJ, United States of America

Geoffrey R Heintzelman


Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 39(Granted Patents)


Company Filing History:


Years Active: 2005-2010

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Geoffrey R. Heintzelman

Introduction

Geoffrey R. Heintzelman is a notable inventor based in Annandale, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for therapeutic applications. With a total of 6 patents to his name, Heintzelman's work has the potential to impact various medical treatments.

Latest Patents

One of Heintzelman's latest patents focuses on "Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods." This invention provides novel arylindenopyridines and arylindenopyrimidines, which are useful for treating disorders that can be ameliorated by antagonizing adenosine A2a receptors. The patent outlines pharmaceutical compositions comprising these compounds and details therapeutic and prophylactic methods utilizing them.

Career Highlights

Throughout his career, Geoffrey R. Heintzelman has worked with prominent companies in the pharmaceutical industry, including Ortho-McNeil Pharmaceutical Corporation and Ortho-Muniel Pharmaceutical, Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Heintzelman has collaborated with notable professionals in his field, including James Lawrence Bullington and Kenneth C. Rupert. These collaborations have likely enriched his research and development efforts, leading to impactful innovations.

Conclusion

Geoffrey R. Heintzelman's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His patents and collaborations reflect a dedication to improving therapeutic methods and addressing critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…